Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.
about
Clinical validity and utility of genetic risk scores in prostate cancerA comparison of genetic risk score with family history for estimating prostate cancer riskImproved prediction of complex diseases by common genetic markers: state of the art and further perspectivesDo environmental factors modify the genetic risk of prostate cancer?Estimating the predictive ability of genetic risk models in simulated data based on published results from genome-wide association studies.An Integrative Genomics Approach for Associating Genome-Wide Association Studies Information With Localized and Metastatic Prostate Cancer PhenotypesImpact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer.Current early diagnostic biomarkers of prostate cancerProstate cancer risk alleles are associated with prostate cancer volume and prostate size.A genetic-based approach to personalized prostate cancer screening and treatment.Do African-American men need separate prostate cancer screening guidelines?Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort.Risk prediction for sporadic Alzheimer's disease using genetic risk score in the Han Chinese populationAssociations Between iCOGS Single Nucleotide Polymorphisms and Upgrading in Both Surgical and Active Surveillance Cohorts of Men with Prostate Cancer.Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical OverviewThe PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate CancerGenetic score is an objective and better measurement of inherited risk of prostate cancer than family history.Prostate cancer risk-associated genetic markers and their potential clinical utilityGenetic scores based on risk-associated single nucleotide polymorphisms (SNPs) can reveal inherited risk of renal cell carcinoma.Personalized prostate cancer care: from screening to treatment.Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.Incorporation of detailed family history from the Swedish Family Cancer Database into the PCPT risk calculatorPrediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs.Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes.Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men.Genome-wide association studies on prostate cancer: the end or the beginning?Multigene panels in prostate cancer risk assessment: a systematic review.Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.The presence of prostate cancer at biopsy is predicted by a number of genetic variants.Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.Multiplex pyrosequencing assay using AdvISER-MH-PYRO algorithm: a case for rapid and cost-effective genotyping analysis of prostate cancer risk-associated SNPsRatio of prostate specific antigen to the outer gland volume of prostrate as a predictor for prostate cancer.Genetic score of multiple risk-associated single nucleotide polymorphisms is a marker for genetic susceptibility to bladder cancer.Genetic risk score to predict biochemical recurrence after radical prostatectomy in prostate cancer: prospective cohort study.Genetic factors influencing prostate cancer risk in Norwegian men.Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
P2860
Q26746219-178E9CDC-B7B0-4B51-8CCF-C741C15D5242Q26752649-99BB84C3-6CA0-45B4-8F24-68B1EB0944A4Q26770167-8405CDDD-AE08-4958-ADF5-909A5BCCBE1FQ30621007-8344FE54-23A1-4DAF-8F58-8F0A6C6325A6Q30834328-5085E2E8-7930-49CB-8EE3-2438D5307FC5Q33565740-874CC005-483B-498B-AB30-1ED8C4DB373BQ33585860-C0191614-50FD-46C1-A493-1D5B5C1B04A3Q33883502-F4F9AE27-C614-46F4-8034-6CFE0E889569Q33922385-33865B69-C885-4D4F-A51F-BF681A5E6290Q33922390-B69F7591-3EB1-44F8-98DF-BCF5C259DB91Q33935064-F567B64F-06A5-410A-BC94-9972EDF9A763Q34802764-59269FE4-B0E8-44C0-BA01-B986E90811F0Q36013706-55DBAE95-5E08-4253-84B4-13D2EBF077C2Q36356134-8983CD26-B3FC-48E7-AA5A-7DFDF629A4C5Q36545643-8AEFBF44-3A51-41F8-B0C3-96786609BC26Q36948336-110E5FF0-8654-4436-8897-10E4B92148F9Q36979944-E39EB90F-AAED-4EFE-8AAF-4DC73FA9C19EQ37017011-478F47A9-5D7F-4F60-B513-9E44A299F341Q37062126-6D708946-3EFB-4743-AD28-87F962223CF7Q37085446-185B8354-58A0-4418-B6B5-61E020E987B1Q37109835-10819968-4563-4D97-9387-54C87C9FC9B6Q37113160-43FB97DA-637E-454B-8FD6-2A50CBA48F0AQ37113165-C84E9960-936A-4050-96D3-7C2A70BBAB64Q37113169-F5BBAAC7-99CF-4B3C-BC52-5685D44CA896Q37279076-51831AFB-00AA-44B8-A5F4-86CFA42F9C5DQ37541290-0D1E6102-516E-43F7-B685-ABA4793972BDQ37541989-0DE9A9A7-FEB0-4EB2-A8A7-EF9204A79950Q37592171-035147E1-3592-4A82-A6A2-49778550EA3FQ38132063-3431C027-6FCE-433B-AB25-B4615D764365Q38596777-C374401B-EDEC-4FB1-BBDB-135DFFA7495DQ40137394-6F4AAF21-B964-4CA6-A63A-6D50F8665697Q40137412-59684841-4E16-4753-8CCB-FCCC41AB134BQ40152616-B412DC4D-148B-483D-B9F9-EC788DD08ECCQ40281207-695B0AA5-979F-4A5D-85FB-8D0A77B79449Q41644041-8B2952D7-428E-4407-9697-733FCD6D94BAQ42073247-1DBE1CE6-30E1-4219-A2A5-4617A262CA88Q44310648-5BBFCF6E-012C-4320-822C-A8F9D8E39D6EQ47171954-C36FC67C-7924-43F5-B206-CDC906A61CF7Q47404155-BA5680AC-701E-4327-B393-2B0B82AB78FFQ47561710-B477FD7B-A0A2-4622-A151-B5FEF754B23C
P2860
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Potential impact of adding gen ...... indings from the REDUCE trial.
@ast
Potential impact of adding gen ...... indings from the REDUCE trial.
@en
type
label
Potential impact of adding gen ...... indings from the REDUCE trial.
@ast
Potential impact of adding gen ...... indings from the REDUCE trial.
@en
prefLabel
Potential impact of adding gen ...... indings from the REDUCE trial.
@ast
Potential impact of adding gen ...... indings from the REDUCE trial.
@en
P2093
P2860
P50
P1433
P1476
Potential impact of adding gen ...... indings from the REDUCE trial.
@en
P2093
A Karim Kader
Aubrey R Turner
Brian H Reck
Brian R Lane
Colin F Spraggs
Deborah A Meyers
Fang-Chi Hsu
Frank M Torti
Greg T Platek
Jeffery M Trent
P2860
P304
P356
10.1016/J.EURURO.2012.05.006
P407
P577
2012-05-12T00:00:00Z